Abbott Laboratories (ABL.HM)
Hamburg - Hamburg Delayed price. Currency in EUR
Add to watchlist
At close: 08:00AM CEST
| Previous close | 99.18 |
| Open | 98.51 |
| Bid | 98.24 x 0 |
| Ask | 98.55 x 0 |
| Day's range | 98.51 - 98.51 |
| 52-week range | 85.26 - 110.94 |
| Volume | |
| Avg. volume | 6 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 18 July 2024 - 22 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.